$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

VHL Disease

Best practice & research. Clinical endocrinology & metabolism, v.24 no.3, 2010년, pp.401 - 413  

Barontini, Marta (Center for Endocrinological Investigations (CEDIE), Hospital de Ninos R. Gutierrez, Buenos Aires, Argentina) ,  Dahia, Patricia L.M. (Dept. Medicine and Cellular &)

Abstract AI-Helper 아이콘AI-Helper

von Hippel-Lindau disease (VHL) disease increases susceptibility to several malignancies, including renal cell carcinoma, haemangioblastomas of the central nervous system or retina and phaeochromocytomas. The VHL tumour suppressor gene, responsible for the disease, encodes for a major regulator of t...

주제어

참고문헌 (90)

  1. Medicine (Baltimore) Maher 76 6 381 1997 10.1097/00005792-199711000-00001 von Hippel-Lindau disease 

  2. Science Latif 260 1317 1993 10.1126/science.8493574 Identification of the von Hippel-Lindau disease tumor suppressor gene 

  3. Cancer Surveys Zbar 25 219 1995 Von Hippel-Lindau disease and sporadic renal cell carcinoma 

  4. Annual Review of Pathology Kaelin 2 145 2007 10.1146/annurev.pathol.2.010506.092049 Von Hippel-Lindau disease 

  5. Clinical Cancer Research Kaelin 10 18 Pt 2 6290S 2004 10.1158/1078-0432.CCR-sup-040025 The von Hippel-Lindau tumor suppressor gene and kidney cancer 

  6. Nature Genetics. Ang 32 4 614 2002 10.1038/ng1019 Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia 

  7. Lancet Lonser 361 9374 2059 2003 10.1016/S0140-6736(03)13643-4 von Hippel-Lindau disease 

  8. Human Molecular Genetics. Clifford 10 10 1029 2001 10.1093/hmg/10.10.1029 Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel- Lindau disease 

  9. Human Molecular Genetics. Hoffman 10 10 1019 2001 10.1093/hmg/10.10.1019 von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF 

  10. Nature Reviews. Cancer Kaelin 2 9 673 2002 10.1038/nrc885 Molecular basis of the VHL hereditary cancer syndrome 

  11. Journal of Neurology, Neurosurgery, and Psychiatry Glasker 67 6 758 1999 10.1136/jnnp.67.6.758 The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system 

  12. Journal of Neurosurgery Neumann 70 1 24 1989 10.3171/jns.1989.70.1.0024 Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome 

  13. Journal of Neurosurgery Wanebo 98 1 82 2003 10.3171/jns.2003.98.1.0082 The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease 

  14. Journal of Medical Genetics Maddock 33 2 120 1996 10.1136/jmg.33.2.120 A genetic register for von Hippel-Lindau disease 

  15. Ophthalmology Webster 106 3 623 1999 10.1016/S0161-6420(99)90127-6 A clinical and molecular genetic analysis of solitary ocular angioma 

  16. Ophthalmology Singh 108 10 1907 2001 10.1016/S0161-6420(01)00758-8 Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease 

  17. Ophthalmology Singh 109 10 1799 2002 10.1016/S0161-6420(02)01177-6 Treatment of retinal capillary hemangioma 

  18. Ophthalmology McCabe 107 12 2240 2000 10.1016/S0161-6420(00)00422-X Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes 

  19. Current Opinion in Ophthalmology Wong 19 3 213 2008 10.1097/ICU.0b013e3282fb7c04 Ocular von Hippel-Lindau disease: clinical update and emerging treatments 

  20. Human Mutation Ong 28 2 143 2007 10.1002/humu.20385 Genotype-phenotype correlations in von Hippel-Lindau disease 

  21. The Journal of Urology Patard 171 6 Pt 1 2181 2004 10.1097/01.ju.0000124846.37299.5e Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience 

  22. Seminars in Oncology Choueiri 33 5 596 2006 10.1053/j.seminoncol.2006.06.003 The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma 

  23. The Journal of Urology Bratslavsky 179 1 67 2008 10.1016/j.juro.2007.08.150 Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes 

  24. The New England Journal of Medicine Yang 349 5 427 2003 10.1056/NEJMoa021491 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer 

  25. Clinical Endocrinology Mukhopadhyay 57 5 603 2002 10.1046/j.1365-2265.2002.01637.x Pancreatic lesions in von Hippel-Lindau disease 

  26. Surgery Blansfield 142 6 814 2007 10.1016/j.surg.2007.09.012 Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs) 

  27. Endocrine Pathology Chetty 15 2 141 2004 10.1385/EP:15:2:141 Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions 

  28. Gastroenterology Hammel 119 4 1087 2000 10.1053/gast.2000.18143 Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau 

  29. The New England Journal of Medicine Lonser 350 24 2481 2004 10.1056/NEJMoa040666 Tumors of the endolymphatic sac in von Hippel-Lindau disease 

  30. Journal of the American Medical Association Butman 298 1 41 2007 10.1001/jama.298.1.41 Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease 

  31. Human Molecular Genetics. Maher 11 20 2347 2002 10.1093/hmg/11.20.2347 The pressure rises: update on the genetics of phaeochromocytoma 

  32. The New England Journal of Medicine Neumann 346 19 1459 2002 10.1056/NEJMoa020152 Germ-line mutations in nonsyndromic pheochromocytoma 

  33. Annals of the New York Academy of Sciences Bausch 1073 122 2006 10.1196/annals.1353.013 Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effort 

  34. The American Surgeon Reddy 66 12 1085 2000 10.1177/000313480006601201 Twenty-five-year surgical experience with pheochromocytoma in children 

  35. Annals of the New York Academy of Sciences Barontini 1073 30 2006 10.1196/annals.1353.003 Characteristics of pheochromocytoma in a 4- to 20-year-old population 

  36. The Journal of Clinical Endocrinology and Metabolism Gaal 94 11 4367 2009 10.1210/jc.2009-1479 Parasympathetic Paragangliomas Are Part of the Von Hippel-Lindau Syndrome 

  37. The Journal of Clinical Endocrinology and Metabolism Eisenhofer 86 5 1999 2001 10.1210/jc.86.5.1999 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes 

  38. Clinical Endocrinology Havekes 2009 New imaging approaches to phaeochromocytomas and paragangliomas 

  39. Journal of Endourology Al-Sobhi 16 3 171 2002 10.1089/089277902753716142 Laparoscopic partial adrenalectomy for recurrent pheochromocytoma after open partial adrenalectomy in von Hippel-Lindau disease 

  40. Clinical Genetics Hes 72 2 122 2007 10.1111/j.1399-0004.2007.00827.x Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification 

  41. Journal of Cellular and Molecular Medicine Santarpia 11 6 1408 2007 10.1111/j.1582-4934.2007.00122.x Mosaicism in von Hippel-Lindau disease: an event important to recognize 

  42. Journal of Pediatric Surgery Ein 25 10 1063 1990 10.1016/0022-3468(90)90219-Y Recurrent pheochromocytomas in children 

  43. Genes Chromosomes Cancer Hering 45 6 602 2006 10.1002/gcc.20323 Characteristic genomic imbalances in pediatric pheochromocytoma 

  44. Japanese Journal of Clinical Oncology Shuin 36 6 337 2006 10.1093/jjco/hyl052 Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment 

  45. American Journal of Kidney Diseases Assadi 41 1 E3 2003 10.1053/ajkd.2003.50021 Bilateral pheochromocytomas and congenital anomalies associated with a de novo germline mutation in the von Hippel-Lindau gene 

  46. Journal of Pediatric Hematology/Oncology Reichardt 24 2 145 2002 10.1097/00043426-200202000-00018 Recurrent polytopic chromaffin paragangliomas in a 9-year-old boy resulting from a novel germline mutation in the von Hippel-Lindau gene 

  47. Journal of Pediatric Endocrinology & Metabolism Ferragut 12 4 579 1999 10.1515/JPEM.1999.12.4.579 Pheochromocytoma and clear-cell renal carcinoma in a child with von Hippel-Lindau disease: a patient report 

  48. Hormone Research. Priesemann 66 1 1 2006 10.1159/000093008 Benefits of screening in von Hippel-Lindau disease-comparison of morbidity associated with initial tumours in affected parents and children 

  49. Journal of Pediatric Surgery Langrehr 42 7 1291 2007 10.1016/j.jpedsurg.2007.02.029 Neuroendocrine tumor of the pancreas and bilateral adrenal pheochromocytomas. A rare manifestation of von Hippel-Lindau disease in childhood 

  50. World Journal of Urology Walther 17 1 35 1999 10.1007/s003450050102 Pheochromocytoma: evaluation, diagnosis, and treatment 

  51. American Journal of Hypertension Sanso 17 12 Pt 1 1107 2004 10.1016/j.amjhyper.2004.06.013 Familial isolated pheochromocytoma presenting a new mutation in the von Hippel-Lindau gene 

  52. Hormone Research. Johnston 55 Suppl. 1 31 2001 10.1159/000063460 Investigating familial endocrine neoplasia syndromes in children 

  53. Pediatric and Developmental Pathology Gaal 1 2009 Neuroendocrine tumors and tumor syndromes in childhood 

  54. Journal of the American Society of Nephrology Kaelin 14 11 2703 2003 10.1097/01.ASN.0000092803.69761.41 The von Hippel-Lindau gene, kidney cancer, and oxygen sensing 

  55. Journal of Internal Medicine Kaelin 243 6 535 1998 10.1046/j.1365-2796.1998.00335.x Functions of the von Hippel-Lindau tumour suppressor protein 

  56. Science Ivan 292 5516 464 2001 10.1126/science.1059817 HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing 

  57. Cell. Epstein 107 1 43 2001 10.1016/S0092-8674(01)00507-4 C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation 

  58. Seminars in Cell & Developmental Biology. Maxwell 13 1 29 2002 10.1006/scdb.2001.0287 Oxygen sensors and angiogenesis 

  59. Cancer Cell. Gordan 14 6 435 2008 10.1016/j.ccr.2008.10.016 HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma 

  60. PLoS Genetics. Dahia 1 1 72 2005 10.1371/journal.pgen.0010008 A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas 

  61. Endocrine-Related Cancer Eisenhofer 11 4 897 2004 10.1677/erc.1.00838 Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome 

  62. Nature Reviews. Cancer Dang 8 1 51 2008 10.1038/nrc2274 The interplay between MYC and HIF in cancer 

  63. Journal of Biological Chemistry Toschi 283 50 34495 2008 10.1074/jbc.C800170200 Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2 

  64. Cancer Research Esteban 66 7 3567 2006 10.1158/0008-5472.CAN-05-2670 Regulation of E-cadherin expression by VHL and hypoxia-inducible factor 

  65. Nature Reviews. Cancer Kaelin 8 11 865 2008 10.1038/nrc2502 The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer 

  66. Development Cho 125 5 803 1998 10.1242/dev.125.5.803 Differential expression and function of cadherin-6 during renal epithelium development 

  67. Cell Cycle Russell 6 1 56 2007 10.4161/cc.6.1.3668 The role of VHL in the regulation of E-cadherin: a new connection in an old pathway 

  68. Molecular Biology of the Cell. Harten 20 3 1089 2009 10.1091/mbc.E08-06-0566 Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin 

  69. Cell Metabolism Kaelin 1 6 357 2005 10.1016/j.cmet.2005.05.006 ROS: really involved in oxygen sensing 

  70. Cell Metabolism Brunelle 1 6 409 2005 10.1016/j.cmet.2005.05.002 Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation 

  71. Cell Metabolism Guzy 1 6 401 2005 10.1016/j.cmet.2005.05.001 Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing 

  72. Cell Metabolism Mansfield 1 6 393 2005 10.1016/j.cmet.2005.05.003 Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation 

  73. The Journal of Biological Chemistry. Block 282 11 8019 2007 10.1074/jbc.M611569200 NAD(P)H oxidases regulate HIF-2alpha protein expression 

  74. Cancer Cell. Maranchie 1 3 247 2002 10.1016/S1535-6108(02)00044-2 The contribution of VHL substrate binding and HIF1- to the phenotype of VHL loss in renal cell carcinoma 

  75. Cancer Cell. Acker 8 2 131 2005 10.1016/j.ccr.2005.07.003 Genetic evidence for a tumor suppressor role of HIF-2alpha 

  76. Nature Cell Biology. Thoma 9 5 588 2007 10.1038/ncb1579 pVHL and GSK3beta are components of a primary cilium-maintenance signalling network 

  77. Cell Cycle Thoma 6 15 1809 2007 10.4161/cc.6.15.4518 The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance 

  78. Molecular Cell. Ohh 1 7 959 1998 10.1016/S1097-2765(00)80096-9 The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix 

  79. Molecular and Cellular Biology. Stickle 24 8 3251 2004 10.1128/MCB.24.8.3251-3261.2004 pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development 

  80. Current Opinion in Oncology Dahia 18 1 1 2006 10.1097/01.cco.0000198017.45982.06 Evolving concepts in pheochromocytoma and paraganglioma 

  81. The Journal of Biological Chemistry. Lipscomb 276 7 5085 2001 10.1074/jbc.M008407200 SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons 

  82. Cancer Cell. Lee 8 2 155 2005 10.1016/j.ccr.2005.06.015 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer 

  83. Hormone and Metabolic Research Qin 41 9 664 2009 10.1055/s-0029-1215590 Pheochromocytomas: from Genetic Diversity to New Paradigms 

  84. Molecular and Cellular Biology. Bishop 28 10 3386 2008 10.1128/MCB.02041-07 Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice 

  85. Genes & Development. Schlisio 22 7 884 2008 10.1101/gad.1648608 The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor 

  86. Human Genetics Yeh 124 3 279 2008 10.1007/s00439-008-0553-1 A germline mutation of the KIF1Bbeta gene on 1p36 in a family with neural and nonneural tumors 

  87. Nature Cell Biology Young 10 3 361 2008 10.1038/ncb1699 VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 

  88. Nature Cell Biology. Thoma 11 8 994 2009 10.1038/ncb1912 VHL loss causes spindle misorientation and chromosome instability 

  89. Cancer Kaelin 115 10 Suppl 2262 2009 10.1002/cncr.24232 Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein 

  90. Current Cancer Drug Targets Konings 9 3 439 2009 10.2174/156800909788166556 The applicability of mTOR inhibition in solid tumors 

관련 콘텐츠

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로